Alzahrani Ali S, Mukhtar Noha, Alhammad Zahrah, Alobaid Lulu, Hakami Abdulrhman Jaber, Alsagheir Osamah, Mohamed Gamal, Hameed Maha, Almahfouz Abdulraof
Department of Medicine, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
Department of Epidemiology, Biostatistics and Scientific Computing, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
J Endocr Soc. 2024 Oct 9;8(11):bvae173. doi: 10.1210/jendso/bvae173. eCollection 2024 Sep 26.
For Muslim patients on levothyroxine (L-T4) therapy, the best approach for L-T4 intake during Ramadan fasting remains unclear.
We compared 2 practical approaches for L-T4 intake during Ramadan.
We randomly assigned 69 patients (21 males, 48 females, median age 44 years) with differentiated thyroid cancer (DTC) who underwent thyroidectomy in the past and are on stable LT4 doses to 2 arms. Arm A (33 patients) ingested their pre-Ramadan L-T4 dose at the evening meal and ate immediately. Arm B (36 patients) increased their pre-Ramadan dose by 25 µg if their regular L-T4 dose was ≤150 µg/day or by 50 µg if their pre-Ramadan dose was >150 µg/day and ate immediately.
At the beginning of Ramadan (baseline), the median thyrotropin (TSH) level and the numbers of patients in euthyroidism, subclinical hyperthyroidism (Shyper), or subclinical hypothyroidism (Shypo) were comparable between the 2 arms ( = .69 and = .65, respectively). At the end of Ramadan, in arm A there were 17 (51.5%), 3 (9.1%), and 13 (39.4%) patients in euthyroidism, Shyper, and Shypo compared with 17 (47.2%), 14 (38.9%), and 5 (13.9%) patients, respectively, in arm B ( = .005). The mean ± SD TSH levels in arms A and B at the end of Ramadan were 5.6 ± 6.0 mU/L and 1.67 ± 2.6 mU/L, respectively ( = .0001).
No overt thyroid dysfunction developed but there were more cases of Shypo in arm A and Shyper in arm B. Arm B achieved desirable levels of TSH (normal or slightly suppressed) in 86% of cases and might be a preferable approach, especially for patients who need TSH suppression (eg, DTC).
对于接受左甲状腺素(L-T4)治疗的穆斯林患者,斋月禁食期间服用L-T4的最佳方法仍不明确。
我们比较了斋月期间服用L-T4的两种实用方法。
我们将69例(21例男性,48例女性,中位年龄44岁)既往接受过甲状腺切除术且L-T4剂量稳定的分化型甲状腺癌(DTC)患者随机分为两组。A组(33例患者)在晚餐时服用斋月前的L-T4剂量并立即进食。B组(36例患者)如果其常规L-T4剂量≤150μg/天,则将斋月前剂量增加25μg;如果其斋月前剂量>150μg/天,则增加50μg,然后立即进食。
在斋月开始时(基线),两组患者的促甲状腺激素(TSH)中位数水平以及甲状腺功能正常、亚临床甲状腺功能亢进(Shyper)或亚临床甲状腺功能减退(Shypo)的患者数量相当(分别为P = 0.69和P = 0.65)。在斋月结束时,A组甲状腺功能正常、Shyper和Shypo的患者分别有17例(51.5%)、3例(9.1%)和13例(39.4%),而B组分别有17例(47.2%)、14例(38.9%)和5例(13.9%)(P = 0.005)。斋月结束时,A组和B组的平均±标准差TSH水平分别为5.6±6.0mU/L和1.67±2.6mU/L(P = 0.0001)。
未出现明显的甲状腺功能障碍,但A组Shypo病例较多,B组Shyper病例较多。B组在86%的病例中达到了理想的TSH水平(正常或轻度抑制),可能是一种更可取的方法,特别是对于需要抑制TSH的患者(如DTC患者)。